MindShift Compounds AG
ActiveLimited or Corporation212000 - Manufacture of pharmaceutical preparations
Biotechnology / Pharmaceutical (Drug Discovery)Biopharmaceutical companies (primary partner identified is MindMed)
MindShift Compounds AG is a Swiss AG registered in Meggen, LU. Its registered activity falls under Manufacture of pharmaceutical preparations.
AI-enriched data· marks AI-enriched fields
AI Insight
Registry narrative generated from SHAB/SOGC facts.
Employees~Small startup; exact number unknown.Officers3Active Relations3Deleted Relations0SOGC Records2First Record29.04.2022Latest Activity17.05.2022BiotechDrug DiscoveryPsychedelicsPharmaceuticalsR&DEmpathogens
Registry Information
- Swiss UID
- CHE-343.594.259
- Legal Name
- MindShift Compounds AG
- Legal Form
- Limited or corporation
- Incorporated
- 18 Sept 2020
- Share Capital
- CHF 100'000.00
- Canton
- LU
- Status
- Active
- Country
- Switzerland
Company Purpose
Translating…
NOGA Codes
(Industry classification)Manufacture of pharmaceutical preparations
CMANUFACTURING21Manufacture of basic pharmaceutical products and pharmaceutical preparations212Manufacture of pharmaceutical preparations2120Manufacture of pharmaceutical preparations212000
Industry Health
Registered Address
Schwerziweg 3
6045, Meggen, LU
Companies at this address
Enrich from integrations
Pull data from your connected providers and merge it with the registry.
Registry Pulse
Registry pulse is a Pro feature
Current Directors & Officers
From the web
Target Customers
Biopharmaceutical companies (primary partner identified is MindMed)
Competitors (3)
ATAI Life Sciences N.V.
Broadly competes with various companies developing therapeutics from the psychedelic drug class and brain health disorder treatments, including ATAI Life Sciences, Compass Pathways, and GH Research.
Compass Pathways plc
Developing COMP360 for treatment-resistant depression.
GH Research plc
Developing psychedelic-based therapeutics for treatment-resistant depression.
Sources (5)
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
prnewswire.com
MindMed strikes partnership with Swiss startup MindShift Compounds to develop and patent next-gen psychedelic compounds | NASDAQ:MNMD, NEO:MMED
proactiveinvestors.com
Mind Medicine (MindMed) - 10-K annual report 2022
companiesmarketcap.com
MindShift Compounds AG, Meggen | OnlineInfo.ch Firmeninformation
onlineinfo.ch
Lustenberger Felix, Meggen, von Kriens und Honau | OnlineInfo.ch Personeninformation
onlineinfo.ch